Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Lupus Erythematosus, Cutaneous: early-phase trial registry

A small indexed set (2 trials) with no open enrollment listed right now.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count

Lupus Erythematosus, Cutaneous: 2 US clinical trials tracked, none currently recruiting.

Lupus Erythematosus, Cutaneous is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 1 of these trials.

Enrollment posture brief

Registry condition lupus-erythematosus-cutaneous

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Lupus Erythematosus, Cut (th…0%
Open-enrollment share among volume-matched conditions near Lupus Erythematosus, Cutaneous

Lupus Erythematosus, Cutaneous has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lupus Erythematosus, Cutaneous on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lupus Erythematosus, Cutaneous is recruiting below its size-band peers.

    0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Lupus Erythematosus, Cutaneous records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

milatuzumab Drug
1 trials
Urine collection Procedure
1 trials
Skin biopsy Procedure
1 trials
Blood collection Procedure
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Lupus Erythematosus, Cutaneous trials. A trial with sites in several states counts in each.

California 2 trials
Utah 1 trials
Pennsylvania 1 trials
New Jersey 1 trials
North Carolina 1 trials
Michigan 1 trials
Massachusetts 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lupus Erythematosus, Cutaneous page

2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Lupus Erythematosus, Cutaneous trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Janssen Research & Development sponsors the most Lupus Erythematosus, Cutaneous trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lupus Erythematosus, Cutaneous condition card totals 2 registered trials; most-linked intervention milatuzumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.